Literature DB >> 35066799

Early Changes and Predictive Value of Serum Histone H3 Concentration in Urosepsis: A Prospective Observational Study.

Xiangcheng Zhan1, Ding Liu2, Yunze Dong1, Yunchen Gao1, Xiao Xu1, Tiancheng Xie1, Hongmin Zhou1, Guangchun Wang1, Haimin Zhang1, Pengfei Wu1, Xulin He3, Chao Sun4, Xudong Yao5, Yunfei Xu6.   

Abstract

INTRODUCTION: To assess early changes in serum histone H3 concentration in patients with urosepsis and its predictive ability for the onset of urosepsis.
METHODS: A total of 80 patients who underwent percutaneous nephrolithotripsy were enrolled in the study and divided into control and urosepsis groups based on their postoperative outcomes. Serum histone H3 concentrations were detected using an enzyme-linked immunosorbent assay, blood indexes were tested by automatic blood analyzers, and vital signs data were obtained by monitors and manual measurements. These results were correlated with the incidence of postoperative urosepsis. Repeated measurements and receiver operating characteristic curves were employed to analyze early changes and the predictive value of serum histone H3 concentration in urosepsis.
RESULTS: Sixteen of the 80 patients (20%) developed urosepsis after surgery. Our data showed significant intra-group differences in terms of postoperative histone H3 concentrations (P < 0.0001) and variation trends (P < 0.0001). Among analyzed blood markers, serum histone H3 concentrations 3 h postoperation [0.825 (95% confidence interval 0.718-0.931, P < 0.0001; cut-off value 256.74 ng/ml, 93.8% sensitivity, 67.2% specificity)] and 6 h post-operation [0.834 (95% CI 0.721-0.947, P < 0.0001, cut-off value 300.875 ng/ml, 68.8% sensitivity, 87.5% specificity)] displayed a higher area under the corresponding receiver operating characteristic curves, indicating that these markers had a decent predictive value for postoperative urosepsis.
CONCLUSION: Our study suggests that serum histone H3 concentration is a novel predictor of postoperative urosepsis in patients undergoing percutaneous nephrolithotripsy. The findings of this study can be validated in a larger cohort. CLINICAL TRIAL REGISTRY NUMBER: ChiCTR1800016679.
© 2022. The Author(s).

Entities:  

Keywords:  Histone H3; Predictive value; Prospective study; Urosepsis

Mesh:

Substances:

Year:  2022        PMID: 35066799      PMCID: PMC8918176          DOI: 10.1007/s12325-021-02026-9

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


Key Summary Points

Introduction

Sepsis has become a leading cause of mortality in hospitalized patients and is characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection [1, 2]. Urosepsis, as the name implies, is sepsis originating from urinary tract infections (UTIs), and it accounts for 25–30% of all sepsis cases [3, 4]. Whether UTIs develop into urosepsis depends on the infection site and the potential for systemic spread. Patients can have an almost harmless UTI transform into severe urosepsis within a short period. Kumar et al. reported that, when sepsis occurs, the survival rate of patients decreases by 8% for every additional hour of administration of sensitive antibiotics [5]. Therefore, early recognition and intervention in urosepsis are key to improving the prognosis of patients. Presently, clinical diagnosis of urosepsis mainly relies on the Sequential Organ Failure Assessment (SOFA) score or quickSOFA score, in addition to evidence of infection (such as the presence of microorganisms in blood and urine culture results), which lack timeliness as urosepsis cannot be predicted before clinical symptoms occur [6-8]. Inflammation-related blood markers, including white blood cells (WBCs), C-reactive protein (CRP), and procalcitonin, are limited in specificity for urosepsis [9-11]. Hence, there is a demand to identify novel early biomarkers with sufficient predictive value in urosepsis for diagnosis before clinical deterioration. Histone H3 is a subtype of histone protein, which has been studied as an inflammatory cytokine for over a decade. Previous studies demonstrated that histone H3 promotes the occurrence of sepsis by damaging endothelial cells, causing pulmonary dysfunction, and inducing disseminated intravascular coagulation (DIC) [12-17]. At the same time, several clinical trials have also confirmed that serum histone H3 concentrations are correlated with high risk of DIC and death in septic patients [18, 19]. Given the promoting effect of histone H3 on urosepsis, we hypothesized that serum histone H3 concentration increases in early stages of urosepsis and could serve as a predictor of the occurrence of urosepsis. To verify this hypothesis, we conducted a prospective observational study to explore the early changes and predictive value of serum histone H3 in urosepsis patients.

Methods

Institutional Review Board and Informed Consent

This study was conducted using a protocol reviewed and approved by the Shanghai Tenth People’s Hospital Ethics Committee (protocol number SHSY-IEC-4.0/19-47/01), and was registered in the Chinese Clinical Trial Registry (ChiCTR1800016679). All eligible patients were contacted by the researchers and were provided with a detailed explanation of the clinical trial. Signed informed consent was obtained from all the participants.

Inclusion and Exclusion Criteria

From June 19 to December 31, 2020, patients admitted to the Department of Urology, Shanghai Tenth People’s Hospital, because of kidney stones who subsequently underwent PCNL were considered potential participants for the study. Further inclusion criteria were: Age > 18 years. Unilateral kidney stones ≥ 2 cm in diameter for which PCNL surgery was performed, with no significant stone residue considered during the surgery. Negative preoperative urine culture test. No infection foci in other organs or preoperative sepsis. Patients who were pregnant, transferred from another hospital with unclear medical history, unable to provide informed consent, or objected to participating at any point during the study were excluded.

Measurement Content

The following measurements were performed for patients: Vital signs: Body temperature was manually measured by infrared thermometer (DT-8806H; CEM, China) which can be accurate to 0.1 °C. Respiratory rate, blood pressure, and heart rate were measured by electrocardiogram monitor (IntelliVue MP50; Philips, USA). Laboratory examination: Blood and urine samples were taken for testing in the Department of Clinical Laboratory within 1 h of admission. Blood samples were tested using an automatic blood analyzer (XE-2100; Sysmex, Japan), urine samples were tested using an automatic urine analyzer (AVE-766; AVE, China), and urine culture was conducted using an automatic microbiological identification and drug sensitivity analysis system (VITEK 2 Compact; Bio Mérieux, France). Serum histone H3 concentration: Blood samples were collected into a serum separator tube and allowed to clot for 2 h at 25 °C before centrifugation for 20 min at approximately 1000g. Once the serum was separated, the histone H3 concentration was subsequently measured using a human histone H3 ELISA kit (RJ-14954; RENJIEBIO, China). All the serum samples were tested twice and averaged to obtain a final serum histone H3 value.

Sample Collection Procedure and Grouping Basis

Blood and urine samples were collected from each patient on admission to the hospital on an empty stomach or after at least 12 h fasting. Samples were used for hematological, blood biochemical, serum histone H3, urine routine, and urine culture tests. All the patients received perisurgical antibiotic prophylaxis according to the European Association of Urology guidelines. Patients underwent preoperative risk assessment, achieved stable blood pressure and blood glucose, no urinary tract infection, with other surgical contraindications excluded, such as tumor in the presumptive access tract area, and fasted 12 h before the surgery. The same chief surgeon operated a 18Fr percutaneous nephroscope (8968.041; Wolf, Germany) and performed the standard PCNL procedure for all patients, with a nephrostomy tube indwelled. Patients returned to their wards after waking from anesthesia. Postoperative blood samples were collected three times at 1, 3, and 6 h after the operation to determine the serum histone H3 concentration, whereas routine blood tests and blood chemistry tests were performed only once at 3 h postoperatively because of the patients’ condition, owing to ethical and economic reasons (Fig. 1). Grouping was determined based on the definition and criteria of Sepsis-3 and the 2020 European Association of Urology guidelines for urosepsis, which identifies sepsis as an increase in the SOFA score of two or more points or a respiratory rate of 22 breaths/min or greater, altered mentation, or systolic blood pressure of 100 mmHg or less for the quickSOFA score [6]. Patients with no postoperative urosepsis were assigned to the control group. As a prospective study, all the samples need to be collected before the clinical outcomes. Therefore, to clarify the time relationship between changes in blood indicators and the onset of urosepsis, we excluded patients who had sepsis before the last blood was obtained 6 h postoperatively (Fig. 2).
Fig. 1

Sample collection procedure. Enrolled patients’ biological samples were collected on admission into the hospital at three postoperative time points. Routine hematological, biochemical, and urine tests were performed once at 3 h postoperative, and serum histone H3 concentrations were measured three times, at 1, 3, and 6 h, postoperatively

Fig. 2

Flowchart for patients enrolled

Sample collection procedure. Enrolled patients’ biological samples were collected on admission into the hospital at three postoperative time points. Routine hematological, biochemical, and urine tests were performed once at 3 h postoperative, and serum histone H3 concentrations were measured three times, at 1, 3, and 6 h, postoperatively Flowchart for patients enrolled

Statistical Analysis

Statistical analyses were conducted using SPSS v.23.0 (IBM, Armonk, NY, USA) and GraphPad Prism 7 (GraphPad Software, Santiago, CA, USA). Continuous variables are expressed as median [interquartile range (IQR)], and categorical variables are expressed as numbers (percentages). The Mann–Whitney U test was used to compare continuous univariate parameters, and the χ2 test was used to compare categorical univariate parameters. Statistical significance was set at P values of < 0.05. Repeated measurements and the one-way analysis of variance followed by the Dunnett’s multiple comparisons test were employed to analyze the differences in serum histone H3 levels over time and between the groups. Receiver operating characteristic (ROC) curves were analyzed to determine the diagnostic value of parameters with statistical significance. Areas under the curve (AUC) were expressed with 95% confidence intervals (CIs).

Results

During the 6-month period, 80 patients who underwent PCNL were enrolled in the study. The average age was 58.36 years (range 24–78 years), and 51 of the enrolled patients were males (64%). In terms of postoperative outcomes, 64 patients had no infection-related complications after the surgery, while 16 patients developed postoperative urosepsis.

Baseline Characteristics of Patients

We collected the patients’ general information and hematological and urine indices (Table 1). There were no significant differences in age, sex, medical history, or blood test results between the two groups. In the urine tests, the proportion of patients with positive urine leukocyte esterase (LE) test results was higher in the urosepsis group than in the control group (14/16 compared to 30/64), and the LE levels were significantly higher in the urosepsis group than in the control group (P < 0.01). However, the urinary WBC count was significantly lower in the urosepsis group than in the control group (P < 0.05).
Table 1

Baseline characteristics of patients

IndexControl (n = 64)Urosepsis (n = 16)UZP
General information
 Age (years old)58.67 (52, 70)57.13 (42, 71)503.5− 0.1020.918
 Male (n, %)42 (65.6)9 (56.3)464− 0.6930.488
 DM (n, %)15 (23.4)4 (25)0.895
 HT (n, %)31 (48.4)8 (50)0.911
Blood
 Biochemical index
  CRP (mg/l)6.37 (0.8, 6.39)4.7 (0.87, 4.5)501.5− 0.0310.976
 Hematological indexes
  WBC (× 109/l)6.5 (5.47, 7.38)7.6 (5.9, 8.64)357.5− 1.8580.063
  RBC (× 1012/l)4.32 (3.98, 4.65)4.39 (4.05, 4.6)468− 0.5290.597
  HB (g/l)133.86 (122, 146)134.38 (122, 146)505− 0.0840.933
  PLT (× 109/l)227.97 (178, 268)241.06 (208, 325)416− 1.1550.248
  Neutrophil (× 109/l)4.18 (3.21, 4.81)4.8 (3.65, 5.51)408− 1.2510.211
  Lymphocyte (× 109/l)1.73 (1.28, 1.98)2.11 (1.53, 2.79)364.5− 1.7740.076
  Monocyte (× 109/l)0.42 (0.33, 0.47)0.43 (0.30, 0.56)505.5− 0.0780.938
Urine
 Urine pH6.1 (6, 6.5)5.91 (5, 6.5)456.5− 0.6940.488
 LE (n, %)< 0.05b
  034 (53.1)2 (12.5)
  1+20 (31.3)7 (43.75)
  2+5 (7.8)3 (18.75)
  3+5 (7.8)4 (25)
 Urine protein (n, %)0.11
  053 (82.8)10 (62.5)
  1+8 (12.5)3 (18.75)
  2+3 (4.7)3 (18.75)
 BLD (n, %)0.31
  012 (18.8)1 (6.25)
  1+14 (21.9)6 (37.5)
  2+6 (9.4)3 (18.75)
  3+18 (28.1)2 (12.5)
  4+14 (21.8)4 (25)
 Urine RBC (n/HP)180.55 (0.5, 39.75)90.31 (4.25, 51.75)504− 0.0970.686
 Urine WBC (n/HP)176.09 (0, 30)55.38 (11.25, 48)330− 2.233< 0.05a
 Urine epithelia (n/HP)2.08 (0, 2)4.25 (0, 2)483− 0.4040.686

Patients’ general information, blood, and urine laboratory test results are displayed. Blood and urine samples were collected on admission to the hospital. Continuous variables are expressed as median values (IQR), and categorial variables are expressed as numbers (percentages)

DM diabetes, HT hypertension, CRP C-reaction protein, WBC white blood cell, RBC red blood cell, HB hemoglobin, PLT platelet, LE leukocyte esterase

aSignificant difference using the Mann–Whitney U test

bSignificant difference using the χ2 test

Baseline characteristics of patients Patients’ general information, blood, and urine laboratory test results are displayed. Blood and urine samples were collected on admission to the hospital. Continuous variables are expressed as median values (IQR), and categorial variables are expressed as numbers (percentages) DM diabetes, HT hypertension, CRP C-reaction protein, WBC white blood cell, RBC red blood cell, HB hemoglobin, PLT platelet, LE leukocyte esterase aSignificant difference using the Mann–Whitney U test bSignificant difference using the χ2 test

Postoperative Laboratory Examination and Vital Sign of Patients

Postoperative blood and urine samples were collected 3 h postoperation, and vital signs were constantly monitored with values at each of the postoperative time points displayed in Table 2. Blood CRP and neutrophil levels were significantly higher (P < 0.05), and lymphocyte levels were lower in the urosepsis group than in the control group (P < 0.05). The patients’ vital signs began to show differences at 3 h postoperatively; we observed higher body temperatures and respiratory rates in patients with urosepsis (P < 0.05); however, no differences were found in the heart rate and blood pressure. A breakdown of the microorganisms isolated from the sepsis patients is included as supplementary material (Table S1).
Table 2

Postoperative indexes of patients

IndexControl (n = 64)Urosepsis (n = 16)UZP
Blood
 Biochemical index
  CRP (mg/l)7.6 (0.8, 3.54)28.45 (2, 54.02)248− 3.181< 0.01a
 Hematological indexes
  WBC (× 109/l)6.97 (4.87, 8.26)9.93 (6.31, 12.92)293.5− 2.628< 0.05a
  RBC (× 1012/l)4.1 (3.81, 4.57)4.08 (3.76, 4.44)476− 0.4330.665
  HB (g/l)128.61 (115, 139)122.94 (108, 142)450− 0.7460.456
  PLT (× 109/l)199.56 (157, 232)192.81 (157.75, 218.25)488− 0.2890.773
  Neutrophil (× 109/l)5.09 (2.96, 6.34)8.58 (5.04, 10.98)230− 3.392< 0.01a
  Lymphocyte (× 109/l)1.42 (1.03, 1.83)0.89 (0.46, 1.21)259.5− 3.037< 0.05a
  Monocyte (× 109/l)0.32 (0.14, 0.4)0.92 (0.06, 0.53)430− 0.9870.324
Vital sign
 1 h T (°C)36.72 (36.5, 37)37.15 (36.5, 37.3)440.5− 0.8790.379
 1 h RR (r/min)18.34 (18, 20)18.69 (18, 20)433− 1.1960.232
 1 h HR (b/min)79.73 (79, 82)83 (80, 84)421.5− 1.1670.243
 1 h Systolic pressure (mmHg)135.56 (129, 141)133.38 (128, 135)426.5− 1.0320.302
 1 h Diastolic pressure (mmHg)81.31 (77, 85)79.94 (75, 84)484− 0.3390.735
 3 h T (°C)36.85 (36.6, 37)37.68 (36.6, 38.5)291− 2.688< 0.05a
 3 h RR (r/min)18.64 (18, 20)26.31 (18, 26)350.5− 2.144< 0.05a
 3 h HR (b/min)80.89 (79, 82)83.31 (79, 98)498− 0.1710.864
 3 h Systolic pressure (mmHg)134 (128, 138)134.06 (130, 140)467− 0.5440.586
 3 h Diastolic pressure (mmHg)79.72 (76, 82)78.06 (71, 82)451− 0.7390.46
 6 h T (°C)37.03 (36.6, 37.5)37.61 (36.7, 38.5)337.5− 2.117< 0.05a
 6 h RR (r/min)18.64 (18, 20)20.81 (18, 24)314.5− 2.64< 0.05a
 6 h HR (b/min)80.31 (80, 82)85.69 (80, 89)412− 1.2250.221
 6 h Systolic pressure (mmHg)129.48 (122, 135)123.81 (108, 133)393− 1.4360.151
 6 h Diastolic pressure (mmHg)79.17 (74, 80)74.06 (70, 82)422.5− 1.0830.279

Patients’ postoperative laboratory test results and vital signs. Blood and urine samples were collected 3 h after the operation, and vital signs were constantly monitored, with values at each of the postoperative time points displayed. Continuous variables are expressed as median values (IQR), and categorial variables are expressed as numbers (percentages)

T temperature, RR respiratory rate, HR heart rate

aSignificant difference using the Mann–Whitney U test

Postoperative indexes of patients Patients’ postoperative laboratory test results and vital signs. Blood and urine samples were collected 3 h after the operation, and vital signs were constantly monitored, with values at each of the postoperative time points displayed. Continuous variables are expressed as median values (IQR), and categorial variables are expressed as numbers (percentages) T temperature, RR respiratory rate, HR heart rate aSignificant difference using the Mann–Whitney U test

Trends in Serum Histone H3 concentrations Over Time in the Two Groups

We examined the serum histone H3 concentrations at each time point in the two groups (Fig. 3). Serum histone H3 concentrations in the control group showed a trend of first increasing and then decreasing, with the peak occurring at 1 h postoperatively. In contrast, in the urosepsis group, the serum histone H3 concentrations increased continually after the surgery, and the differences in histone H3 concentrations 6 h postoperatively compared to histone H3 concentrations before the operation and 1 h postoperatively were statistically significant (P < 0.0001 before the operation and P < 0.01 1 h postoperatively).
Fig. 3

Trends in serum histone H3 concentrations over time in the two groups. Blood samples were collected at different time points before and after the surgery. A Serum histone H3 concentrations at each time point in the control group. Mean ± SEM, n = 64, no significant difference was found. B Serum histone H3 concentrations at each time point in the urosepsis group. Mean ± SEM, n = 16, ****P < 0.0001 compared to preoperative concentrations. SEM standard error of mean

Trends in serum histone H3 concentrations over time in the two groups. Blood samples were collected at different time points before and after the surgery. A Serum histone H3 concentrations at each time point in the control group. Mean ± SEM, n = 64, no significant difference was found. B Serum histone H3 concentrations at each time point in the urosepsis group. Mean ± SEM, n = 16, ****P < 0.0001 compared to preoperative concentrations. SEM standard error of mean

Comparison of Each Time Point’s Serum Histone H3 Concentrations Between the Two Groups.

We compared the serum histone H3 concentrations at each time point in both groups (Fig. 4). Before the operation, serum histone H3 concentrations in both groups were below 200 μg/ml, with no significant differences between them (Fig. 4A). The histone H3 concentrations in both the groups increased by 1 h postoperatively, but no differences were observed (Fig. 4B). However, differences began to show 3 h postoperatively where the histone H3 concentrations in the urosepsis group continued to increase and were significantly higher than those in the control group (P < 0.0001) (Fig. 4C, D).
Fig. 4

Comparison of serum histone H3 levels at each time point between the two groups. Blood samples were collected at different time points before and after the surgery. A–D Each groups’ serum histone H3 concentrations at each time point. Mean ± SEM, control n = 64, urosepsis n = 16, ****P < 0.0001, when compared to the control group at 3 h and 6 h postoperatively

Comparison of serum histone H3 levels at each time point between the two groups. Blood samples were collected at different time points before and after the surgery. A–D Each groups’ serum histone H3 concentrations at each time point. Mean ± SEM, control n = 64, urosepsis n = 16, ****P < 0.0001, when compared to the control group at 3 h and 6 h postoperatively

Inter-group Differences in Trends in Serum Histone H3 Concentration Over Time

To better understand inter-group differences in trends in the serum histone H3 concentration over time, we performed repeated measurements (Table 3). The Mauchly’s test of sphericity revealed that the significance of within-subject effects of histone H3 concentration was 0.118 (P > 0.05), which required the Greenhouse–Geisser correction. Further tests of within-subject effects with the Greenhouse–Geisser correction showed significant differences between the groups (P < 0.0001), and indicated that patients in the urosepsis group had greater changes in serum histone H3 concentrations over time than those in the control group. The trend graph clearly shows these differences between the groups (Fig. 5).
Table 3

Repeated measurement of inter-group differences of histone H3

Within subjects effectsMauchly's WApprox. χ2P
Mauchly’s test of sphericity
 Histone H30.8928.7930.118

Repeated measurement of inter-group differences of histone H3. Results of Mauchly’s test of sphericity and tests of within-subject effects with Greenhouse–Geisser correction are displayed

aSignificance of intra-group serum histone H3 changes over time

bSignificance of inter-group serum histone H3 changes over time

Fig. 5

Trend graph of serum histone H3 concentrations over time in the two groups. The x-axis represents time of measurement, and the y-axis represents histone H3 level (μg/ml). Blue line changing histone H3 concentrations in the control group over time; green line changing histone H3 concentrations in the urosepsis group over time; red arrow indicates the point at which a significant trend difference can be observed between the groups

Repeated measurement of inter-group differences of histone H3 Repeated measurement of inter-group differences of histone H3. Results of Mauchly’s test of sphericity and tests of within-subject effects with Greenhouse–Geisser correction are displayed aSignificance of intra-group serum histone H3 changes over time bSignificance of inter-group serum histone H3 changes over time Trend graph of serum histone H3 concentrations over time in the two groups. The x-axis represents time of measurement, and the y-axis represents histone H3 level (μg/ml). Blue line changing histone H3 concentrations in the control group over time; green line changing histone H3 concentrations in the urosepsis group over time; red arrow indicates the point at which a significant trend difference can be observed between the groups

Diagnostic Capability of Parameters with Significant Differences

Patients who developed urosepsis had significant differences in several parameters of postoperative blood tests and vital signs, as well as in serum histone H3 concentrations compared with patients in the control group (Table 2; Figs. 3 and 4). To further explore the diagnostic capability of each parameter, we generated the ROC curves. Vital signs, postoperative temperature, and respiratory rate at 3 h and 6 h postoperatively, were included in one ROC curve. The AUC values were 0.716 for temperature 3 h postoperatively (95% CI 0.546–0.886, P = 0.087), 0.658 for respiratory rate 3 h postoperatively (95% CI 0.473–0.842, P = 0.052), 0.670 for temperature 6 h postoperatively (95% CI 0.483–0.858, P = 0.036), and 0.693 for respiratory rate 6 h postoperatively (95% CI 0.529–0.856, P = 0.018) (Fig. 6).
Fig. 6

ROC for postoperative vital signs. AUC values for temperature and respiratory rate 3 h postoperatively were 0.716 and 0.658, respectively, and those for temperature and respiratory rate 6 h operatively were 0.670 and 0.693, respectively

ROC for postoperative vital signs. AUC values for temperature and respiratory rate 3 h postoperatively were 0.716 and 0.658, respectively, and those for temperature and respiratory rate 6 h operatively were 0.670 and 0.693, respectively Blood CRP levels, WBC counts, neutrophil counts, and lymphocyte levels, which were measured only once 3 h postoperatively, have been included in another ROC curve. The AUC values were 0.758 for CRP levels (95% CI 0.633–0.883, P < 0.001, cut-off value 1.995 mg/l, 81.3% sensitivity, 64.1% specificity), 0.713 for leukocyte counts (95% CI 0.570–0.857, P = 0.009, cut-off value 8.73 × 109/l, 56.3% sensitivity, 79.7% specificity), 0.775 for neutrophil levels (95% CI 0.647–0.904, P < 0.001, cut-off value 5.92 × 109/L, 75% sensitivity, 73.4% specificity), and 0.747 for lymphocyte counts (95% CI 0.617–0.876, P = 0.002, cut-off value 1.115 × 109/L, 75% sensitivity, 68.7% specificity) (Fig. 7).
Fig. 7

ROC for postoperative blood indexes. AUC values for blood CRP, leukocyte, neutrophil, and lymphocyte were 0.758, 0.713, 0.775, and 0.747, respectively

ROC for postoperative blood indexes. AUC values for blood CRP, leukocyte, neutrophil, and lymphocyte were 0.758, 0.713, 0.775, and 0.747, respectively Postoperative serum histone H3 concentrations were also assessed using the ROC curve. The AUC for histone H3 concentration at each time point was 0.455 1 h postoperatively (95% CI 0.253–0.657, P = 0.580), 0.825 3 h postoperatively (95% CI 0.718–0.931, P < 0.0001, cut-off value 256.74 μg/ml, 93.8% sensitivity, 67.2% specificity), and 0.834 6 h postoperatively (95% CI 0.721–0.947, P < 0.0001, cut-off value 300.875 μg/ml, 68.8% sensitivity, 87.5% specificity) (Fig. 8). Based on these ROC curves, after abandoning parameters whose AUC values were below 0.7 and P > 0.05, the diagnostic capability of each parameter from most efficient to least efficient was histone H3 concentrations 6 h postoperatively (0.834), histone H3 concentrations 3 h postoperatively (0.825), neutrophil counts (0.775), CRP levels (0.758), lymphocyte counts (0.747), and leukocyte counts (0.713).
Fig. 8

ROC of postoperative serum histone H3. AUC values for serum histone H3 concentration 1 h, 3 h, and 6 h postoperatively were 0.455, 0.825, and 0.834, respectively

ROC of postoperative serum histone H3. AUC values for serum histone H3 concentration 1 h, 3 h, and 6 h postoperatively were 0.455, 0.825, and 0.834, respectively

Discussion

Urosepsis has long been a challenging problem in clinical urology. Seeking biomarkers that can be used to predict the occurrence of urosepsis may contribute to the early diagnosis of urosepsis and improve the prognosis of septic patients. Based on previous studies, we supposed that serum histone H3 is the biomarker with such potential. We enrolled 80 patients who underwent PCNL procedure and grouped them according to their post-operative outcomes, serum histone H3 concentrations were compared with established blood markers and clinical manifestations in terms of diagnostic efficiency. As a result, we demonstrated that serum histone H3 concentrations can be an adequate predictor for the onset of urosepsis. Since the revision of the international consensus of Sepsis-3, the diagnosis rate of sepsis has greatly improved, revealing sepsis to be among the most serious complications in patients after PCNL, with an incidence ranging from 3.5 to 35.05% [20-24]. The release of kidney stone-colonizing bacteria and other bacterial endotoxins during surgery into the circulation system coupled with elevated renal pelvis pressure is believed to be the main cause of postoperative infection and urosepsis [25, 26]. Therefore, kidney stones themselves are a potential source of infection, which may explain why some of the patients’ urine culture results turned positive after surgery, and they subsequently developed urosepsis. A patient’s vital signs are often the first indication of postoperative outcomes, even before the ability to establish a urosepsis diagnosis. We found differences in body temperature and respiratory rate 3 and 6 h postoperatively; however, the results of the ROC analysis showed that either their AUC values were less than 0.7 or the results were not statistically significant, implying that they have limited diagnostic value for the occurrence of postoperative urosepsis (Fig. 6). Nevertheless, it is undeniable that vital signs remain a fundamental basis for diagnosing sepsis and septic shock. Extracellular histone H3 is mainly phagocytosed and cleared by monocytes and macrophages [27, 28]. However, when a patient is under severe trauma or experiences inflammation or other pathological conditions, large amounts of extracellular histone H3 are released into blood circulation from necrotic cells and neutrophil extracellular traps, which subsequently exerts its damage-associated molecular pattern effects by activating inflammatory pathways; thus, damaging the vascular endothelium, and triggering platelet aggregation and clotting [14, 29–34]. Additionally, extracellular histone H3 can significantly impair the clearing ability of macrophages [35], thus forming a vicious cycle of continued accumulation of extracellular H3 and progression of inflammatory processes in the body, which considerably contribute to the occurrence of sepsis. This may explain the transient increase in histone H3 concentrations in the control group within a short period of time after surgery and the differences in the trend in serum histone H3 concentrations over time between the urosepsis and control groups. In fact, multiple studies have reported elevated histone H3 concentrations in sepsis patients [18, 19, 36, 37]. Additionally, it is worth noting that our research shows that serum histone H3 concentrations at 3 and 6 h postoperatively had a better predictive efficiency for the occurrence of urosepsis than other blood indicators (AUC, 0.825 and 0.834, respectively). Therefore, the clinical application of postoperative serum histone H3 concentration detection may help in the early diagnosis of urosepsis and improve patient prognosis. This study had several limitations. First, this was a single-center trial with relatively few enrolled cases, and true clinical promotion and application requires larger-scale experimental validation. Second, as this was a prospective study with ethical limitations, our monitoring of serum histone H3 concentrations only lasted until 6 h after the surgery; therefore, we could not detect subsequent changes to investigate the relationship between histone H3 concentrations and urosepsis severity. We expect to explore the correlations among histone H3 concentrations, SOFA scores, and patient prognosis in further studies. In conclusion, serum histone H3 concentrations and its early postoperative changes in patients with postoperative urosepsis were significantly different from those in patients without postoperative urosepsis. Therefore, serum histone H3 concentrations may serve as an indicator for predicting the occurrence of postoperative urosepsis, which will contribute to the early diagnosis of urosepsis, in order to help recognize potential patients and improve their prognosis; however, further larger-scale studies are required to validate these results. Below is the link to the electronic supplementary material. Supplementary file1 (PDF 497 KB)
Urosepsis is a disorder response to urinary tract infection which causes life-threatening organ dysfunction.
Finding biomarkers for early diagnosis may help identify potential uroseptic patients and improve their prognosis.
Serum histone H3 concentration increases significantly at the early stage of urosepsis.
Serum histone H3 concentration could serve as a predictor of the onset of urosepsis.
  29 in total

1.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

2.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

3.  Management of Sepsis and Septic Shock.

Authors:  Michael D Howell; Andrew M Davis
Journal:  JAMA       Date:  2017-02-28       Impact factor: 56.272

Review 4.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Crit Care Med       Date:  2003-04       Impact factor: 7.598

Review 5.  The Use of Biomarkers in Sepsis: A Systematic Review.

Authors:  Konstantinos Giannakopoulos; Ursula Hoffmann; Uzair Ansari; Thomas Bertsch; Martin Borggrefe; Ibrahim Akin; Michael Behnes
Journal:  Curr Pharm Biotechnol       Date:  2017       Impact factor: 2.837

6.  Immunology. Getting sepsis therapy right.

Authors:  Richard S Hotchkiss; Edward R Sherwood
Journal:  Science       Date:  2015-03-13       Impact factor: 47.728

Review 7.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

8.  Extracellular histones are major mediators of death in sepsis.

Authors:  Jun Xu; Xiaomei Zhang; Rosana Pelayo; Marc Monestier; Concetta T Ammollo; Fabrizio Semeraro; Fletcher B Taylor; Naomi L Esmon; Florea Lupu; Charles T Esmon
Journal:  Nat Med       Date:  2009-10-25       Impact factor: 53.440

9.  Circulating histones are mediators of trauma-associated lung injury.

Authors:  Simon T Abrams; Nan Zhang; Joanna Manson; Tingting Liu; Caroline Dart; Florence Baluwa; Susan Siyu Wang; Karim Brohi; Anja Kipar; Weiping Yu; Guozheng Wang; Cheng-Hock Toh
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

Review 10.  PAMPs and DAMPs: signal 0s that spur autophagy and immunity.

Authors:  Daolin Tang; Rui Kang; Carolyn B Coyne; Herbert J Zeh; Michael T Lotze
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.